CA2874881A1 - Use of substituted nitrostyrenes in the treatement of scedosporium spp infection - Google Patents

Use of substituted nitrostyrenes in the treatement of scedosporium spp infection Download PDF

Info

Publication number
CA2874881A1
CA2874881A1 CA2874881A CA2874881A CA2874881A1 CA 2874881 A1 CA2874881 A1 CA 2874881A1 CA 2874881 A CA2874881 A CA 2874881A CA 2874881 A CA2874881 A CA 2874881A CA 2874881 A1 CA2874881 A1 CA 2874881A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
hydrogen
hydroxy
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874881A
Other languages
English (en)
French (fr)
Inventor
Julie Phillips
Tania Sorrell
Sharon Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biodiem Ltd
Original Assignee
Biodiem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902243A external-priority patent/AU2012902243A0/en
Application filed by Biodiem Ltd filed Critical Biodiem Ltd
Publication of CA2874881A1 publication Critical patent/CA2874881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2874881A 2012-05-30 2013-05-13 Use of substituted nitrostyrenes in the treatement of scedosporium spp infection Abandoned CA2874881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902243 2012-05-30
AU2012902243A AU2012902243A0 (en) 2012-05-30 Method of treating Seedosporium spp. infection
PCT/AU2013/000487 WO2013177608A1 (en) 2012-05-30 2013-05-13 Method of treating scedosporium spp. infection

Publications (1)

Publication Number Publication Date
CA2874881A1 true CA2874881A1 (en) 2013-12-05

Family

ID=49672167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874881A Abandoned CA2874881A1 (en) 2012-05-30 2013-05-13 Use of substituted nitrostyrenes in the treatement of scedosporium spp infection

Country Status (9)

Country Link
US (1) US9867802B2 (enExample)
EP (1) EP2854799B1 (enExample)
JP (1) JP2015518007A (enExample)
CN (1) CN104519882A (enExample)
AU (2) AU2013204604B2 (enExample)
CA (1) CA2874881A1 (enExample)
SG (1) SG11201407924RA (enExample)
WO (1) WO2013177608A1 (enExample)
ZA (1) ZA201408975B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661496A4 (en) * 2017-08-01 2021-04-21 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS WITH SUBSTITUTED NITROSTYRENE COMPOUNDS
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
JPS585902B2 (ja) * 1978-09-01 1983-02-02 株式会社大塚製薬工場 β↓−ニトロスチレン誘導体
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
US20080220103A1 (en) * 2005-10-24 2008-09-11 Jay Birnbaum Method for treating/controlling/killing fungi and bacteria on living animals
AU2006306690A1 (en) * 2005-10-24 2007-05-03 Staval Pharma, Ltd. Method for treating/controlling/killing fungi and bacteria
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
UA107963C2 (xx) * 2010-06-07 2015-03-10 Janssen Pharmaceutica Nv ПРОТИГРИБКОВІ ПОХІДНІ 5,6-ДИГІДРО-4-$(ДИФТОРЕТИЛ)ФЕНІЛ]-4H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ І 4-(ДИФТОРЕТИЛ)ФЕНІЛ-6H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ

Also Published As

Publication number Publication date
AU2013204604B2 (en) 2016-05-19
JP2015518007A (ja) 2015-06-25
WO2013177608A1 (en) 2013-12-05
EP2854799A1 (en) 2015-04-08
SG11201407924RA (en) 2014-12-30
US20150126436A1 (en) 2015-05-07
EP2854799B1 (en) 2018-04-25
ZA201408975B (en) 2016-10-26
CN104519882A (zh) 2015-04-15
AU2013204604A1 (en) 2013-12-19
AU2013270430A1 (en) 2014-12-18
EP2854799A4 (en) 2015-10-21
US9867802B2 (en) 2018-01-16
HK1209052A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
US9867802B2 (en) Method of treating Scedosporium spp. infection
ES2963057T3 (es) Forma cristalina de ribósido de nicotinamida
US7989652B2 (en) C-nitroso-derived nitroxyl donors
US7825145B2 (en) Antimicrobial and radioprotective compounds
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
JP6215827B2 (ja) キサントン化合物の誘導体
TW201945005A (zh) 硼酸化合物、藥物組成物及所述化合物的用途
CN1088068C (zh) 子囊霉素
BRPI0719187A2 (pt) Composto heterocíclicos úteis como agentes anábolicos para animais de criação
JP2004501901A (ja) イミノピリミジン系ｎｍｄａｎｒ２ｂ受容体拮抗薬
JP5997779B2 (ja) 抗寄生虫薬としてのジヒドロフランアゼチジン誘導体
AU2002311088A1 (en) Antimicrobial and radioprotective compounds
US10239885B1 (en) Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
RU2434867C2 (ru) Производные бензохинолизин-2-карбоновой кислоты
US20260069585A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
HK1209052B (en) 3,4-methylenedioxy-beta-methyl-beta-nitrostyrene for use in the treatment of scedosporium spp. infection
WO2022105825A1 (en) Compounds as pu. 1 inhibitors
CN115536607A (zh) 一种杂原子取代的芳香类化合物及其制备方法和用途
EA011024B1 (ru) Антигельминтные производные имидазола и тиазола
US20150223463A1 (en) Spirocyclic isoxazoline derivatives for treatment of sea lice
ES2986502T3 (es) Agente antifúngico
CN114478391B (zh) 奥硝唑酯类前药、药物组合物及其制备方法和应用
JP2023542455A (ja) ３－デオキシ－２－ケトアルドン酸窒素含有誘導体、その製造方法及びその使用
US20260069553A1 (en) TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES
WO2025047793A1 (ja) 抗真菌薬に対する活性増強作用を有する新規化合物及びその製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180405

FZDE Discontinued

Effective date: 20220131